BioCardia Inc. (BCDA)
1.93
0.02 (1.05%)
At close: Apr 17, 2025, 3:59 PM
1.92
-0.52%
After-hours: Apr 17, 2025, 04:05 PM EDT
1.05% (1D)
| Bid | 1.9 |
| Market Cap | 9.03M |
| Revenue (ttm) | 58K |
| Net Income (ttm) | -7.95M |
| EPS (ttm) | -2.9 |
| PE Ratio (ttm) | -0.67 |
| Forward PE | -1.35 |
| Analyst | Buy |
| Ask | 2.2 |
| Volume | 2,448 |
| Avg. Volume (20D) | 66,788 |
| Open | 1.94 |
| Previous Close | 1.91 |
| Day's Range | 1.92 - 1.94 |
| 52-Week Range | 1.63 - 6.15 |
| Beta | 1.21 |
About BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 1996
Employees 17
Stock Exchange NASDAQ
Ticker Symbol BCDA
Website https://www.biocardia.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BCDA stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 1195.34% from the latest price.
Stock Forecasts2 months ago
+3.65%
BioCardia shares are trading higher after the comp...
Unlock content with
Pro Subscription
5 months ago
-14.04%
BioCardia shares are trading higher. The company reported Q3 financial results.
